Novobiotic has implemented new culturing technologies that improve access to uncultured microbes. These technologies include the “iChip”, a miniaturized device that allows isolation and cultivation of new microbes in a single step.
The majority of microorganisms in nature that are potentially novel drug sources remain inaccessible for novel antibiotic discovery. In contrast, Novobiotic’s collection is made up of many novel species and genera only distantly related to known microorganisms. Multiple drug leads have been identified from producing organisms of this collection.